Sign In
Buy 0VJA
Sun Life Financial Earnings Calls
| Release date | Nov 05, 2025 |
| EPS estimate | $1.83 |
| EPS actual | $1.86 |
| EPS Surprise | 1.64% |
| Revenue estimate | 1.315B |
| Revenue actual | 1.447B |
| Revenue Surprise | 10.00% |
| Release date | Aug 07, 2025 |
| EPS estimate | $1.77 |
| EPS actual | $1.29 |
| EPS Surprise | -27.12% |
| Revenue estimate | - |
| Revenue actual | 8.466B |
| Release date | May 08, 2025 |
| EPS estimate | $1.70 |
| EPS actual | $1.82 |
| EPS Surprise | 7.06% |
| Revenue estimate | - |
| Revenue actual | - |
| Release date | Feb 12, 2025 |
| EPS estimate | $1.77 |
| EPS actual | $0.441 |
| EPS Surprise | -75.09% |
| Revenue estimate | - |
| Revenue actual | 8.56B |
Last 4 Quarters for Sun Life Financial
Below you can see how 0VJA.L performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 12, 2025 |
| Price on release | $83.12 |
| EPS estimate | $1.77 |
| EPS actual | $0.441 |
| EPS surprise | -75.09% |
| Date | Price |
|---|---|
| Feb 06, 2025 | $83.12 |
| Feb 07, 2025 | $83.12 |
| Feb 10, 2025 | $83.12 |
| Feb 11, 2025 | $83.12 |
| Feb 12, 2025 | $83.12 |
| Feb 13, 2025 | $78.12 |
| Feb 14, 2025 | $78.12 |
| Feb 17, 2025 | $78.12 |
| Feb 18, 2025 | $78.12 |
| 4 days before | 0% |
| 4 days after | -6.02% |
| On release day | -6.02% |
| Change in period | -6.02% |
| Release date | May 08, 2025 |
| Price on release | $83.58 |
| EPS estimate | $1.70 |
| EPS actual | $1.82 |
| EPS surprise | 7.06% |
| Date | Price |
|---|---|
| May 02, 2025 | $82.09 |
| May 05, 2025 | $82.09 |
| May 06, 2025 | $82.09 |
| May 07, 2025 | $83.58 |
| May 08, 2025 | $83.58 |
| May 09, 2025 | $83.58 |
| May 12, 2025 | $83.58 |
| May 13, 2025 | $83.58 |
| May 14, 2025 | $83.58 |
| 4 days before | 1.82% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 1.82% |
| Release date | Aug 07, 2025 |
| Price on release | $90.30 |
| EPS estimate | $1.77 |
| EPS actual | $1.29 |
| EPS surprise | -27.12% |
| Date | Price |
|---|---|
| Aug 01, 2025 | $90.30 |
| Aug 04, 2025 | $90.30 |
| Aug 05, 2025 | $90.30 |
| Aug 06, 2025 | $90.30 |
| Aug 07, 2025 | $90.30 |
| Aug 08, 2025 | $90.30 |
| Aug 11, 2025 | $78.68 |
| Aug 12, 2025 | $78.68 |
| Aug 13, 2025 | $78.68 |
| 4 days before | 0% |
| 4 days after | -12.87% |
| On release day | 0% |
| Change in period | -12.87% |
| Release date | Nov 05, 2025 |
| Price on release | $82.54 |
| EPS estimate | $1.83 |
| EPS actual | $1.86 |
| EPS surprise | 1.64% |
| Date | Price |
|---|---|
| Oct 30, 2025 | $82.54 |
| Oct 31, 2025 | $82.54 |
| Nov 03, 2025 | $82.54 |
| Nov 04, 2025 | $82.54 |
| Nov 05, 2025 | $82.54 |
| Nov 06, 2025 | $82.54 |
| Nov 07, 2025 | $82.54 |
| Nov 10, 2025 | $82.54 |
| Nov 11, 2025 | $82.54 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
Sun Life Financial Earnings Call Transcript Summary of Q3 2025
Sun Life delivered a solid Q3 2025 driven by strong results in Asia and Canada and continued momentum in Asset Management, while U.S. health businesses (group, dental, medical stop-loss) underperformed and are being actively repriced. Key financials: underlying EPS $1.86 (+6% YoY), underlying net income $1.047B (+3% YoY), underlying ROE 18.3%, book value per share +3% Q/Q, LICAT ratio 154%. Capital actions: common dividend increased by $0.04 to $0.92/share, ~ $400M of share repurchases in the quarter, and continued preparation for an ~ $2B SLC-related purchase next year. Asset Management highlights: $1.6T AUM (with $1.4T managed by SLAM businesses and $1.2T third-party), MFS institutional wins and improving flows, SLC on track to hit its 2025 earnings target. Asia saw double-digit protection sales and record earnings; Canada showed strong protection sales and fee income growth. U.S. results were impacted by higher claims frequency and cost in dental and stop-loss; management emphasizes these businesses are repriceable over 1–3 years and expects gradual improvement with disciplined pricing, expense actions and cost containment. The company reiterated medium-term objectives: ~10% underlying earnings growth, ~20% ROE and dividend payout ratio 40–50%.
